Skip to main content
SpringerLink
Log in

The Role of P-Glycoprotein in Psychiatric Disorders and in Psychiatric Treatment

  • Chapter
  • First Online:
PET and SPECT in Psychiatry

  • 1636 Accesses

Abstract

With regard to protection of the brain, the endothelial capillary cell harbours an important efflux pump on its surface, called P-glycoprotein (P-gp). This multispecific pump has a large capacity and is capable of extruding an unusual broad range of potentially toxic substances from the brain. Some research findings suggest that this pump plays a role in neuropsychiatric disorders, since these disorders have inflammatory features that are associated with decreased function of P-gp. Other studies have indicated that many of the current antidepressant and antipsychotic agents may modulate the function of P-gp.

In this review, we discuss the current state of knowledge concerning the role of P-glycoprotein on pharmacokinetics of psychiatric drugs and the impact of modulation of P-glycoprotein on major psychiatric disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Achira M, Suzuki H, Ito K et al (1999) Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1(4):E18

    PubMed  CAS  Google Scholar 

  • Adkison KD, Shen DD (1996) Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276(3):1189–1200

    PubMed  CAS  Google Scholar 

  • Aller SG, Yu J, Ward A et al (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323(5922):1718–1722

    PubMed Central  PubMed  CAS  Google Scholar 

  • Ambroziak K, Kuteykin-Teplyakov K, Luna-Tortos C et al (2010) Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol 628(1):57–66

    PubMed  CAS  Google Scholar 

  • Aronica E, Gorter JA, Jansen GH et al (2003) Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 118(2):417–429

    PubMed  CAS  Google Scholar 

  • Baltes S, Gastens AM, Fedrowitz M et al (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52(2):333–346

    PubMed  CAS  Google Scholar 

  • Banerjee S, Bhat MA (2007) Neuron-glial interactions in blood–brain barrier formation. Annu Rev Neurosci 30:235–258

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bartels AL, Kortekaas R, Bart J et al (2008a) Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 30:1818–1824

    PubMed  Google Scholar 

  • Bartels AL, Willemsen AT, Kortekaas R et al (2008b) Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm 115(7):1001–1009

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bauer M, Karch R, Neumann F et al (2009) Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol 65(9):941–946

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bauer M, Zeitlinger M, Karch R et al (2012) Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood–brain barrier: a comparison with rat data. Clin Pharmacol Ther 91(2):227–233

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bernacki J, Dobrowolska A, Nierwinska K et al (2008) Physiology and pharmacological role of the blood–brain barrier. Pharmacol Rep 60(5):600–622

    PubMed  CAS  Google Scholar 

  • Chandler N, Jacobson S, Esposito P et al (2002) Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice. Brain Behav Immun 16(6):757–763

    PubMed  CAS  Google Scholar 

  • Chaudhuri JD (2000) Blood brain barrier and infection. Med Sci Monit 6(6):1213–1222

    PubMed  CAS  Google Scholar 

  • Choi YK, Kim KW (2008) Blood-neural barrier: its diversity and coordinated cell-to-cell communication. BMB Rep 41(5):345–352

    PubMed  CAS  Google Scholar 

  • Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25(4):231–259

    PubMed  CAS  Google Scholar 

  • Cooray HC, Blackmore CG, Maskell L et al (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13(16):2059–2063

    PubMed  CAS  Google Scholar 

  • de Klerk OL, Willemsen ATM, Roosink M et al (2009) Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood–brain barrier. Int J Neuropsychopharmacol 12(7):895–904

    PubMed  Google Scholar 

  • de Klerk OL, Bosker FJ, Willemsen AT et al (2010a) Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood–brain barrier: an experimental PET study in rat. J Psychopharmacol 24(8):1237–1242

    PubMed  Google Scholar 

  • de Klerk OL, Willemsen AT, Bosker FJ et al (2010b) Regional increase in P-glycoprotein function in the blood–brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res 183(2):151–156

    PubMed  Google Scholar 

  • de Klerk OL, Nolte IM, Bet PM et al (2012) ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. doi:10.1038/tpj.2012.16

    PubMed  Google Scholar 

  • Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14(1):3–9

    PubMed  Google Scholar 

  • Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14(11):1189–1197

    PubMed  CAS  Google Scholar 

  • Dijkstra IM, Hulshof S, van der Valk P et al (2004) Cutting edge: activity of human adult microglia in response to CC chemokine ligand 21. J Immunol 172(5):2744–2747

    PubMed  CAS  Google Scholar 

  • Dong C, Wong ML, Licinio J (2009) Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 14(12):1105–1118

    PubMed Central  PubMed  CAS  Google Scholar 

  • Doran A, Obach RS, Smith BJ et al (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33(1):165–174

    PubMed  CAS  Google Scholar 

  • Duffy KR, Pardridge WM (1987) Blood–brain barrier transcytosis of insulin in developing rabbits. Brain Res 420(1):32–38

    PubMed  CAS  Google Scholar 

  • Ejsing TB, Pedersen AD, Linnet K (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol 20(7):493–500

    PubMed  CAS  Google Scholar 

  • Ejsing TB, Hasselstrom J, Linnet K (2006) The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol Drug Interact 21:139–162

    PubMed  Google Scholar 

  • El Ela AA, Hartter S, Schmitt U et al (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56(8):967–975

    PubMed  Google Scholar 

  • Elsinga PH, Hendrikse NH, Bart J et al (2005) Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 7(1):37–44

    PubMed  Google Scholar 

  • Esposito P, Jacobson S, Connolly R et al (2001) Non-invasive assessment of blood–brain barrier (BBB) permeability using a gamma camera to detect 99technetium-gluceptate extravasation in rat brain. Brain Res Protoc 8(2):143–149

    CAS  Google Scholar 

  • Fox PT, Raichle ME, Mintun MA et al (1988) Nonoxidative glucose consumption during focal physiologic neural activity. Science 241(4864):462–464

    PubMed  CAS  Google Scholar 

  • Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25(8):423–429

    PubMed  CAS  Google Scholar 

  • Fukui N, Suzuki Y, Sawamura K et al (2007) Dose-dependent effects of the 3435 C> T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 29(2):185–189

    PubMed  CAS  Google Scholar 

  • Gelisse P, Hillaire-Buys D, Halaili E et al (2007) Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris) 163(11):1096–1099

    CAS  Google Scholar 

  • Ghotbi R, Mannheimer B, Aklillu E et al (2010) Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure–an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 66(5):465–474

    PubMed  CAS  Google Scholar 

  • Gomez-Gonzalez B, Escobar A (2009) Altered functional development of the blood–brain barrier after early life stress in the rat. Brain Res Bull 79(6):376–387

    PubMed  CAS  Google Scholar 

  • Grant GA, Abbott NJ, Janigro D (1998) Understanding the physiology of the blood–brain barrier: in vitro models. News Physiol Sci 13:287–293

    PubMed  CAS  Google Scholar 

  • Grauer MT, Uhr M (2004) P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 18(1):66–74

    PubMed  CAS  Google Scholar 

  • Gudmundsson P, Skoog I, Waern M et al (2007) The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 15(10):832–838

    PubMed  Google Scholar 

  • Guillemin GJ, Brew BJ (2004) Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 75(3):388–397

    PubMed  CAS  Google Scholar 

  • Hamann GF, Schimrigk K (1995) What is the relevance of the endothelins in subarachnoid haemorrhage? J Neurol Neurosurg Psychiatry 58(3):392

    PubMed Central  PubMed  CAS  Google Scholar 

  • Hamm S, Dehouck B, Kraus J et al (2004) Astrocyte mediated modulation of blood–brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts. Cell Tissue Res 315(2):157–166

    PubMed  Google Scholar 

  • Hartz AM, Bauer B, Fricker G et al (2004) Rapid regulation of P-glycoprotein at the blood–brain barrier by endothelin-1. Mol Pharmacol 66(3):387–394

    PubMed  CAS  Google Scholar 

  • Hartz AM, Bauer B, Fricker G et al (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood–brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 69(2):462–470

    PubMed  CAS  Google Scholar 

  • Hawkins BT, Davis TP (2005) The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57(2):173–185

    PubMed  CAS  Google Scholar 

  • Hendrikse NH, Schinkel AH, de Vries EG et al (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood–brain barrier visualized with positron emission tomography. Br J Pharmacol 124(7):1413–1418

    PubMed Central  PubMed  CAS  Google Scholar 

  • Henry CB, Duling BR (1999) Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 2772(Pt 2):H508–H514

    Google Scholar 

  • Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97(7):3473–3478

    PubMed Central  PubMed  CAS  Google Scholar 

  • Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23(5):477–501

    PubMed  CAS  Google Scholar 

  • Iadecola C (1993) Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link? Trends Neurosci 16(6):206–214

    PubMed  CAS  Google Scholar 

  • Jedlitschky G, Leier I, Buchholz U et al (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54(18):4833–4836

    PubMed  CAS  Google Scholar 

  • Jefferies WA, Brandon MR, Hunt SV et al (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312(5990):162–163

    PubMed  CAS  Google Scholar 

  • Jiang S, Su C, Ballok D (2008) Astrocytes and astrocyte-derived factors in the blood–brain barrier in health and disease. In: Helio TR (ed) The blood brain barrier. 1st7. Nova Science Publishers, New York, pp 153–168

    Google Scholar 

  • Jones AR, Shusta EV (2007) Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24(9):1759–1771

    PubMed Central  PubMed  CAS  Google Scholar 

  • Jovanovic N, Bozina N, Lovric M et al (2010) The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66(11):1109–1117

    PubMed  CAS  Google Scholar 

  • Jover F, Cuadrado JM, Andreu L et al (2002) Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 25(5):251–253

    PubMed  CAS  Google Scholar 

  • Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152–162

    PubMed  CAS  Google Scholar 

  • Kanai Y, Endou H (2003) Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci 28(1):1–17

    PubMed  CAS  Google Scholar 

  • Kannan P, John C, Zoghbi SS et al (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368–377

    PubMed Central  PubMed  CAS  Google Scholar 

  • Karssen AM, Meijer OC, van der Sandt I et al (2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142(6):2686–2694

    PubMed  CAS  Google Scholar 

  • Kato M, Fukuda T, Serretti A et al (2008) ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32(2):398–404

    PubMed  CAS  Google Scholar 

  • Kessler RC, Berglund P, Demler O et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105

    PubMed  Google Scholar 

  • Kirschbaum KM, Henken S, Hiemke C et al (2008) Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 188(2):298–303

    PubMed  CAS  Google Scholar 

  • Kirschbaum KM, Uhr M, Holthoewer D et al (2010) Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59(6):474–479

    PubMed  CAS  Google Scholar 

  • Kreisl WC, Liow JS, Kimura N et al (2010) P-glycoprotein function at the blood–brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 51(4):559–566

    PubMed Central  PubMed  CAS  Google Scholar 

  • Kuzman MR, Medved V, Bozina N et al (2008) The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 160(3):308–315

    PubMed  CAS  Google Scholar 

  • Laika B, Leucht S, Steimer W (2006) ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52(5):893–895

    PubMed  CAS  Google Scholar 

  • Lazarowski A, Massaro M, Schteinschnaider A et al (2004) Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther Drug Monit 26(1):44–46

    PubMed  Google Scholar 

  • Lee YJ, Maeda J, Kusuhara H et al (2006) In vivo evaluation of P-glycoprotein function at the blood–brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 316(2):647–653

    PubMed  CAS  Google Scholar 

  • Leung JW, Chung SS, Chung SK (2009) Endothelial endothelin-1 over-expression using receptor tyrosine kinase tie-1 promoter leads to more severe vascular permeability and blood brain barrier breakdown after transient middle cerebral artery occlusion. Brain Res 1266:121–129

    PubMed  CAS  Google Scholar 

  • Lin YC, Ellingrod VL, Bishop JR et al (2006) The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 28(5):668–672

    PubMed  CAS  Google Scholar 

  • Lin KM, Chiu YF, Tsai IJ et al (2011) ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21(4):163–170

    PubMed  CAS  Google Scholar 

  • Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18(3):157–169

    PubMed  CAS  Google Scholar 

  • Liu X, Chen C, Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325(2):349–356

    PubMed  CAS  Google Scholar 

  • Lombardo L, Pellitteri R, Balazy M et al (2008) Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 5(2):82–92

    PubMed  CAS  Google Scholar 

  • Lubberink M, Luurtsema G, van Berckel BN et al (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 27(2):424–433

    PubMed  CAS  Google Scholar 

  • Luna-Tortos C, Fedrowitz M, Loscher W (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55(8):1364–1375

    PubMed  CAS  Google Scholar 

  • Maes M, Yirmyia R, Noraberg J et al (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53

    PubMed  CAS  Google Scholar 

  • Maines LW, Antonetti DA, Wolpert EB et al (2005) Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49(5):610–617

    PubMed  CAS  Google Scholar 

  • Mason BL, Pariante CM, Jamel S et al (2010) Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers and nonbarrier regions. Endocrinology 151(11):5294–5305

    PubMed Central  PubMed  CAS  Google Scholar 

  • Matsson P, Englund G, Ahlin G et al (2007) A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323(1):19–30

    PubMed  CAS  Google Scholar 

  • Matsson P, Pedersen JM, Norinder U et al (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26(8):1816–1831

    PubMed  CAS  Google Scholar 

  • Matter K, Balda MS (2003) Functional analysis of tight junctions. Methods 30(3):228–234

    PubMed  CAS  Google Scholar 

  • McRae MP, Brouwer KL, Kashuba AD (2003) Cytokine regulation of P-glycoprotein. Drug Metab Rev 35(1):19–33

    PubMed  CAS  Google Scholar 

  • Mihaljevic PA, Bozina N, Sagud M et al (2008) MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32(6):1439–1444

    Google Scholar 

  • Mintun MA, Lundstrom BN, Snyder AZ et al (2001) Blood flow and oxygen delivery to human brain during functional activity: theoretical modeling and experimental data. Proc Natl Acad Sci U S A 98(12):6859–6864

    PubMed Central  PubMed  CAS  Google Scholar 

  • Miura M, Uno T, Tateishi T et al (2007) Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 19(3):223–227

    PubMed  CAS  Google Scholar 

  • Murck H (2002) Magnesium and affective disorders. Nutr Neurosci 5(6):375–389

    PubMed  CAS  Google Scholar 

  • O’Brien SM, Scott LV, Dinan TG (2004) Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19(6):397–403

    PubMed  Google Scholar 

  • Okamura T, Kikuchi T, Okada M et al (2009) Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J Cereb Blood Flow Metab 29(3):504–511

    PubMed  CAS  Google Scholar 

  • Omidi Y, Barar J, Ahmadian S et al (2008) Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochem Funct 26(3):381–391

    PubMed  CAS  Google Scholar 

  • Ott M, Huls M, Cornelius MG et al (2010) St. John’s Wort constituents modulate P-glycoprotein transport activity at the blood–brain barrier. Pharm Res 27(5):811–822

    PubMed  CAS  Google Scholar 

  • Pardridge WM (2002a) Drug and gene delivery to the brain: the vascular route. Neuron 36(4):555–558

    PubMed  CAS  Google Scholar 

  • Pardridge WM (2002b) Neurotrophins, neuroprotection and the blood–brain barrier. Curr Opin Investig Drugs 3(12):1753–1757

    PubMed  CAS  Google Scholar 

  • Pardridge WM (2005) Molecular biology of the blood–brain barrier. Mol Biotechnol 30(1):57–70

    PubMed  CAS  Google Scholar 

  • Pardridge WM (2006) Molecular Trojan horses for blood–brain barrier drug delivery. Curr Opin Pharmacol 6(5):494–500

    PubMed  CAS  Google Scholar 

  • Pariante CM, Makoff A, Lovestone S et al (2001) Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134(6):1335–1343

    PubMed Central  PubMed  CAS  Google Scholar 

  • Pedersen JM, Matsson P, Bergstrom CA et al (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51(11):3275–3287

    PubMed  CAS  Google Scholar 

  • Peer D, Dekel Y, Melikhov D et al (2004) Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64(20):7562–7569

    PubMed  CAS  Google Scholar 

  • Perlis RH, Fijal B, Dharia S et al (2010) Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67(11):1110–1113

    PubMed  CAS  Google Scholar 

  • Peters EJ, Slager SL, Kraft JB et al (2008) Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 3(4):e1872

    PubMed Central  PubMed  Google Scholar 

  • Qian W, Homma M, Itagaki F et al (2006) MDR1 Gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 29(12):2446–2450

    PubMed  CAS  Google Scholar 

  • Ramsauer M, Krause D, Dermietzel R (2002) Angiogenesis of the blood–brain barrier in vitro and the function of cerebral pericytes. FASEB J 16(10):1274–1276

    PubMed  CAS  Google Scholar 

  • Rao VV, Dahlheimer JL, Bardgett ME et al (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96(7):3900–3905

    PubMed Central  PubMed  CAS  Google Scholar 

  • Renes J, de Vries EG, Nienhuis EF et al (1999) ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126(3):681–688

    PubMed Central  PubMed  CAS  Google Scholar 

  • Roberts DJ, Goralski KB (2008) A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 4(10):1245–1264

    PubMed  CAS  Google Scholar 

  • Roberts RL, Joyce PR, Mulder RT et al (2002) A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2(3):191–196

    PubMed  CAS  Google Scholar 

  • Sarginson JE, Lazzeroni LC, Ryan HS et al (2010) ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 20(8):467–475

    PubMed  CAS  Google Scholar 

  • Sasongko L, Link JM, Muzi M et al (2005) Imaging P-glycoprotein transport activity at the human blood–brain barrier with positron emission tomography. Clin Pharmacol Ther 77(6):503–514

    PubMed  CAS  Google Scholar 

  • Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29(2):201–217

    PubMed  CAS  Google Scholar 

  • Schinkel AH, Wagenaar E, Mol CA et al (1996) P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):2517–2524

    PubMed Central  PubMed  CAS  Google Scholar 

  • Seneca N, Zoghbi SS, Liow JS et al (2009) Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med 50(5):807–813

    PubMed Central  PubMed  CAS  Google Scholar 

  • Sharom FJ (2006) Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84(6):979–992

    PubMed  CAS  Google Scholar 

  • Sheehan NL, Brouillette MJ, Delisle MS et al (2006) Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 40(1):147–150

    PubMed  Google Scholar 

  • Singh P, Kaur J, Kaur P et al (2009) Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+. Bioorg Med Chem 17(6):2423–2427

    PubMed  CAS  Google Scholar 

  • Sinton CM, Fitch TE, Petty F et al (2000) Stressful manipulations that elevate corticosterone reduce blood–brain barrier permeability to pyridostigmine in the rat. Toxicol Appl Pharmacol 165(1):99–105

    PubMed  CAS  Google Scholar 

  • Sirot Jacqenoud EM, Knezevic BM, Morena GPM et al (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29(4):319–326

    Google Scholar 

  • Slot AJ, Wise DD, Deeley RG et al (2008) Modulation of human multidrug resistance protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites. Drug Metab Dispos 36(3):552–560

    PubMed  CAS  Google Scholar 

  • Smith QR, Stoll J (1998) Blood–brain barrier amino acid transport. In: Pardridge WM (ed) Introduction to the blood–brain barrier. 1st20. Cambridge University Press, Cambridge, pp 188–197

    Google Scholar 

  • Störmer E, von Moltke LL, Perloff MD et al (2001) P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol 41(7):708–714

    PubMed  Google Scholar 

  • Sukhai M, Piquette-Miller M (2000) Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 3(2):268–280

    PubMed  CAS  Google Scholar 

  • Syvanen S, Hammarlund-Udenaes M (2010) Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr Top Med Chem 10(17):1799–1809

    PubMed  Google Scholar 

  • Szabo D, Szabo G Jr, Ocsovszki I et al (1999) Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139(1):115–119

    PubMed  CAS  Google Scholar 

  • Tan KH, Purcell WM, Heales SJ et al (2002) Evaluation of the role of P-glycoprotein in inflammation induced blood–brain barrier damage. Neuroreport 13(18):2593–2597

    PubMed  CAS  Google Scholar 

  • Thoeringer CK, Wultsch T, Shahbazian A et al (2009) Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. Psychoneuroendocrinology 32(8–10):1028–1040, 2007

    Google Scholar 

  • Tsuji A (2005) Small molecular drug transfer across the blood–brain barrier via carrier-mediated transport systems. NeuroRx 2(1):54–62

    PubMed Central  PubMed  Google Scholar 

  • Ueda K, Okamura N, Hirai M et al (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267(34):24248–24252

    PubMed  CAS  Google Scholar 

  • Uhr M, Grauer MT (2003) abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37(3):179–185

    PubMed  Google Scholar 

  • Uhr M, Steckler T, Yassouridis A et al (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood–brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22(4):380–387

    PubMed  CAS  Google Scholar 

  • Uhr M, Grauer MT, Holsboer F (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54(8):840–846

    PubMed  CAS  Google Scholar 

  • Uhr M, Grauer MT, Yassouridis A et al (2007) Blood–brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 41(1):179–188

    PubMed  Google Scholar 

  • Uhr M, Tontsch A, Namendorf C et al (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57(2):203–209

    PubMed  CAS  Google Scholar 

  • Urquhart BL, Kim RB (2009) Blood–brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65(11):1063–1070

    PubMed  CAS  Google Scholar 

  • Volk HA, Burkhardt K, Potschka H et al (2004) Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123(3):751–759

    PubMed  CAS  Google Scholar 

  • Wagner CC, Bauer M, Karch R et al (2009) A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood–brain barrier with (R)-11C-verapamil and PET. J Nucl Med 50(12):1954–1961

    PubMed Central  PubMed  Google Scholar 

  • Wang JS, Taylor R, Ruan Y et al (2003) Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29(3):551–557, American College of Neuropsychopharmacology

    CAS  Google Scholar 

  • Wang JS, Ruan Y, Taylor RM et al (2004) The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7(4):415–419, Cambridge Journals Online

    PubMed  CAS  Google Scholar 

  • Wang JS, Zhu HJ, Markowitz JS et al (2006) Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187(4):415–423

    CAS  Google Scholar 

  • Wang JS, Zhu HJ, Gibson BB et al (2008) Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 31(2):231–234

    PubMed Central  PubMed  CAS  Google Scholar 

  • Wang JS, Zhu HJ, Donovan JL et al (2009) Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 110(1–3):90–94

    PubMed  Google Scholar 

  • Warren MS, Zerangue N, Woodford K et al (2009) Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 59(6):404–413

    PubMed  CAS  Google Scholar 

  • Weber CC, Kressmann S, Ott M et al (2005) Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 38(6):293–300

    PubMed  CAS  Google Scholar 

  • Weber CC, Eckert GP, Muller WE (2006) Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology 31(11):2443–2448

    PubMed  CAS  Google Scholar 

  • Weiss J, Dormann SM, Martin-Facklam M et al (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305(1):197–204

    PubMed  CAS  Google Scholar 

  • Wolburg H, Lippoldt A (2002) Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul Pharmacol 38(6):323–337

    PubMed  CAS  Google Scholar 

  • Xing Q, Gao R, Li H et al (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7):987–993

    PubMed  CAS  Google Scholar 

  • Yang HW, Liu HY, Liu X et al (2008) Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett 434(3):299–303

    PubMed  CAS  Google Scholar 

  • Yasui-Furukori N, Mihara K, Takahata T et al (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57(5):569–575

    PubMed Central  PubMed  CAS  Google Scholar 

  • Yu XQ, Xue CC, Wang G et al (2007) Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr Drug Metab 8(8):787–802

    PubMed  CAS  Google Scholar 

  • Zhang Y, Schuetz JD, Elmquist WF et al (2004) Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 311(2):449–455

    PubMed  CAS  Google Scholar 

  • Zhao R, Raub TJ, Sawada GA et al (2009) Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood–brain barrier. Drug Metab Dispos 37(6):1251–1258

    PubMed Central  PubMed  CAS  Google Scholar 

  • Zhou SF, Wang LL, Di YM et al (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15(20):1981–2039

    PubMed  CAS  Google Scholar 

  • Ziylan YZ, Baltaci AK, Mogulkoc R (2009) Leptin transport in the central nervous system. Cell Biochem Funct 27(2):63–70

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Topreferent Trauma Center, Geestelijke Gezondheids Zorg Drenthe, Dennenweg 9, Assen, 9404 RA, The Netherlands

    Onno L. de Klerk

Authors
  1. Onno L. de Klerk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Onno L. de Klerk .

Editor information

Editors and Affiliations

  1. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Rudi A.J.O. Dierckx

  2. Faculty of Electrical Engineering and Information Technology, University of Applied Sciences Offenburg, Offenburg, Germany

    Andreas Otte

  3. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Erik F. J. de Vries

  4. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Aren van Waarde

  5. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), Groningen, The Netherlands

    Johan A. den Boer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

de Klerk, O.L. (2014). The Role of P-Glycoprotein in Psychiatric Disorders and in Psychiatric Treatment. In: Dierckx, R., Otte, A., de Vries, E., van Waarde, A., den Boer, J. (eds) PET and SPECT in Psychiatry. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40384-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40384-2_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40383-5

  • Online ISBN: 978-3-642-40384-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation